RxDoctor Payments DataLook up a doctor →

Howard Weintraub, MD

Cardiovascular Disease · New York, NYNPI 1457347767

Payments from drug & device makers

$1,659,481in general payments, 2019–2025

Across 949 payments — averaging $1748.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$548K
  • Novartis$325K
  • Novo Nordisk AS$286K
  • Eli Lilly$220K
  • Novo Nordisk$192K
  • Amarin Pharma, Inc.$23K
  • plus $65K from 25 others
$14,848in research payments, 2019–2025

Across 3 payments — averaging $4949.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$12K
  • Novartis$3K

What the payments were for

  • Consulting fees$61,66619%
  • Speaking & faculty fees$243,87474%
  • Travel & lodging$6,8072%
  • Food & beverage$15,5035%
  • Education$890%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,659,481 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$61,198
Medicare patients
300
Services billed
667

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab167$195,779
EliquisApixaban164$169,047
JardianceEmpagliflozin89$103,460
Praluent PenAlirocumab79$72,071
OzempicSemaglutide39$55,161
EntrestoSacubitril/Valsartan27$34,780
VascepaIcosapent Ethyl43$32,272
BrilintaTicagrelor31$21,977
NexletolBempedoic Acid20$16,008
Ezetimibe402$11,564
Icosapent Ethyl33$10,889
Eplerenone57$5,759
Rosuvastatin Calcium349$4,975
Atorvastatin Calcium369$3,886
Metoprolol Succinate176$2,747

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$342$169,047164 claims
Boehringer IngelheimJardiance$4,145$103,46089 claims
Novo NordiskOzempic$192,369$55,16139 claims
NovartisEntresto$324,944$34,78027 claims
AstraZenecaBrilinta$11,282$21,97731 claims
Esperion Therapeutics, Inc.Nexletol$15,014$16,00820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →